pyrroles has been researched along with celecoxib in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (51.43) | 29.6817 |
| 2010's | 15 (42.86) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Alvaro-Gracia, JM | 1 |
| Busse, R; Falck, JR; Fleming, I; Michaelis, UR; Schmidt, R | 1 |
| Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X | 1 |
| Hirota, T; Ikeda, T; Inoue, S; Kawai, K; Koyama, K; Oitate, M | 1 |
| Kopelovich, L; Patlolla, JM; Rao, CV; Reddy, BS; Steele, VE; Swamy, MV | 1 |
| Alexandova, A; Georgieva, A; Kesiova, M; Kirkova, M; Todorov, S; Tsvetanova, E | 1 |
| Bijev, A; Bocheva, A; Stoev, G; Yaneva, D | 1 |
| Alexandova, A; Kesiova, M; Kirkova, M; Todorov, S | 1 |
| Bandy, DP; Daniels, SE; Desjardins, PJ; Lawson, JE; Link, AJ; Moberly, JB; Truitt, KE; Xu, J | 1 |
| Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X | 1 |
| Lin, Y; Reddy, BS; Xiao, H; Yang, CS; Zhang, Q | 1 |
| Klein, T; Pushkareva, MA; Shephard, P; Sud'ina, GF | 1 |
| Kapoor, S | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Xiao, H; Yang, CS | 1 |
| Chu, F; Feng, Z; Guo, Z; Sun, P | 1 |
| Jin, H; Koo, PT; Tsang, DJ; Xiao, H; Yang, CS; Yang, Z | 1 |
| Freĭdlin, IS; Kiseleva, EP; Kuznetsova, SA; Liamina, IV; Starikova, EA | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Alsop, DC; Atkins, MB; Bahamon, B; Bhatt, RS; Goldberg, SN; Mier, JW; O'Neill, A; Signoretti, S; Wang, X; Wood, CG; Zhang, L | 1 |
| Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Chen, S; Conney, AH; Cui, XX; Dipaola, RS; Goodin, S; He, Y; Huang, H; Li, D; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Brosh, T; Chechik, O; Dolkart, O; Gabet, Y; Liron, T; Maman, E; Somjen, D | 1 |
| Balansky, R; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Nikolov, M; Steele, VE | 1 |
| Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
| Chu, Y; Guo, J; Hu, X; Wang, G; Zhao, Q | 1 |
| Gao, GM; Jiang, DB; Kan, QC; Li, YM; Liu, SY; Xu, PH; Zhang, LL; Zheng, XL; Zheng, ZH | 1 |
| Abdellatif, KRA; El-Magd, MA; Elshaier, YAMM; Fadaly, WAA; Kamel, GM | 1 |
| Delev, D; Deneva, T; Kostadinov, I; Kostadinova, I; Vladimirova, S; Zlatanova, H | 1 |
| Choi, HY; Jang, C; Lee, JY; Lee, KT; Park, CS; Youn, I; Yune, TY | 1 |
| Guo, W; Li, J; Liu, Y | 1 |
| Chen, KM; Chu, YR; Tong, WQ; Wang, C; Wang, JX; Wang, XL; Xu, SQ; Zong, HX | 1 |
2 review(s) available for pyrroles and celecoxib
| Article | Year |
|---|---|
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Combinations; Gastrointestinal Diseases; Humans; Isoenzymes; Lipoxygenase Inhibitors; Long-Term Care; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Sulfonamides | 2004 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
3 trial(s) available for pyrroles and celecoxib
| Article | Year |
|---|---|
A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
Topics: Acute Disease; Adolescent; Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Molar, Third; Pain Measurement; Pain, Postoperative; Pyrazoles; Pyrroles; Sulfonamides; Tooth Extraction; Tooth, Impacted; Treatment Outcome | 2007 |
The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
Topics: Biomarkers; Celecoxib; Demography; Follow-Up Studies; Humans; Inflammation; Intercellular Signaling Peptides and Proteins; Pyrroles; Spondylarthritis; Sulfides; Treatment Outcome | 2017 |
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study.
Topics: Analgesia; Celecoxib; Humans; Meperidine; Pain, Postoperative; Pyrroles; Sulfides | 2022 |
30 other study(ies) available for pyrroles and celecoxib
| Article | Year |
|---|---|
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; 8,11,14-Eicosatrienoic Acid; Amino Acid Sequence; Aryl Hydrocarbon Hydroxylases; Carbazoles; Celecoxib; Cells, Cultured; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; DNA, Antisense; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Epoprostenol; Humans; Indoles; Membrane Proteins; Molecular Sequence Data; Morphogenesis; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Recombinant Fusion Proteins; RNA, Messenger; Stress, Mechanical; Sulfaphenazole; Sulfonamides; Transcription Factors; Transduction, Genetic; Umbilical Veins | 2005 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celecoxib; Cell Growth Processes; Colonic Neoplasms; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Pyrazoles; Pyrroles; Rats; Rats, Inbred F344; Sulfonamides | 2006 |
Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
Topics: Animals; Aorta, Thoracic; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2 Inhibitors; Elastin; Lactones; Male; Protein Binding; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution | 2006 |
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Apoptosis; Atorvastatin; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Pyrazoles; Pyrroles; Sulfonamides | 2006 |
Potential antioxidant activity of celecoxib and amtolmetin guacyl: in vitro studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Celecoxib; Deoxyribose; Free Radicals; Gastric Mucosa; Glycine; Intestinal Mucosa; Liver; Male; Nitroblue Tetrazolium; Oxidation-Reduction; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides | 2007 |
Ligand-based design, synthesis and primary in vivo screening of pyrrole derivatives as potential tricyclic anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Carrageenan; Celecoxib; Chromatography, Thin Layer; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Edema; Foot; Injections, Intraperitoneal; Ligands; Magnetic Resonance Spectroscopy; Male; Mice; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Structure-Activity Relationship; Sulfonamides | 2006 |
In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catalase; Celecoxib; Colon; Cyclooxygenase 2 Inhibitors; Diclofenac; Gastric Mucosa; Glucosephosphate Dehydrogenase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glycine; Lipid Peroxidation; Liver; Male; Oxyphenonium; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds; Sulfonamides; Thiobarbituric Acid Reactive Substances; Tolmetin | 2007 |
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
Topics: Apoptosis; Atorvastatin; Celecoxib; Cell Cycle; Cell Survival; Colonic Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G1 Phase; GTP-Binding Proteins; HCT116 Cells; Heptanoic Acids; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; MAP Kinase Kinase 4; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrroles; Resting Phase, Cell Cycle; Signal Transduction; Sulfonamides; Time Factors | 2008 |
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acid; Blood; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; Humans; Indoles; Isoenzymes; Lipoxygenase Inhibitors; Molecular Structure; Neutrophils; Pyrazoles; Pyrroles; Random Allocation; Sulfonamides | 2008 |
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2008 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents | 2008 |
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Edema; Humans; Mice; Pyrazoles; Pyrroles; Rats; Sulfides; Sulfonamides | 2009 |
Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.
Topics: Atorvastatin; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Chromans; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Polyisoprenyl Phosphates; Pyrazoles; Pyrroles; Sulfonamides; Vitamin E | 2010 |
[Effect of sutent and celecoxib on the properties of endothelial cells in vitro].
Topics: 5'-Nucleotidase; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Celecoxib; Cell Movement; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Indoles; Pyrazoles; Pyrroles; Sulfonamides; Sunitinib | 2009 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Mice; Pyrazoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2014 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Heptanoic Acids; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
Topics: Animals; Atorvastatin; Biomechanical Phenomena; Celecoxib; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrazoles; Pyrroles; Random Allocation; Rats, Wistar; Receptors, Prostaglandin E, EP4 Subtype; Rotator Cuff; Sulfonamides; Tendons; Wound Healing | 2014 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Precancerous Conditions; Pyrroles; Smoking; Survival Rate; Toxicity Tests, Subchronic | 2015 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasm Transplantation; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Regulatory | 2017 |
Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors.
Topics: alpha-Glucosidases; Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cellulases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Glycoside Hydrolase Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Pyrroles; Rats; Sheep; Stomach Ulcer; Structure-Activity Relationship; Thiazolidines | 2019 |
Biological Screening of Novel Structural Analog of Celecoxib as Potential Anti-Inflammatory and Analgesic Agent.
Topics: Analgesics; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Blood Platelets; Carrageenan; Celecoxib; Drug Evaluation, Preclinical; Edema; Erythrocytes; Hemoglobins; Indoles; Leukocytes; Male; Models, Animal; Pain Measurement; Pyrroles; Rats; Rats, Wistar | 2019 |
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.
Topics: Animals; Cauda Equina; Celecoxib; Chronic Pain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Hyperalgesia; Lumbar Vertebrae; Macrophages; Male; Neuralgia; Pyrroles; Rats, Sprague-Dawley; Spinal Stenosis | 2019 |
A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
Topics: Axial Spondyloarthritis; Celecoxib; Humans; Pyrroles; Sulfides; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2022 |